A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer
Small Methods · 2024
DOI: 10.1002/smtd.202300747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2024. Verfasst von Yijiu Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cell-Free Nucleic Acids, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Shanghai Pulmonary Hospital Innovation Team, Shanghai Science and Technology Committee, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Low‐dose computed tomography screening can increase the detection for non‐small‐cell lung cancer (NSCLC). To improve the diagnostic accuracy of early‐stage NSCLC detection, ultrasensitive methods are used to detect cell‐free DNA (cfDNA) 5‐hydroxymethylcytosine (5hmC) in plasma. Genome‐wide 5hmC is profiled in 1990 cfDNA samples collected from patients with non‐small cell lung cancer (NSCLC, n = 727), healthy controls (HEA, n = 1,092), as well as patients with small cell lung cancer (SCLC, n = 41), followed by sample randomization, differential analysis, feature selection, and modeling using a machine learning approach. Differentially modified features reflecting tissue origin. A weighted diagnostic model comprised of 105 features is developed to compute a detection score for each individual, which showed an area under the curve (AUC) range of 86.4%–93.1% in the internal and external validation sets for distinguishing lung cancer from HEA controls, significantly outperforming serum biomarkers ( p < 0.001). The 5hmC‐based model detected high‐risk pulmonary nodules (AUC: 82%)and lung cancer of different subtypes with high accuracy as well. A highly sensitive and specific blood‐based test is developed for detecting lung cancer. The 5hmC biomarkers in cfDNA offer a promising blood‐based test for lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
- Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- Shanghai Epican Genetech, Co., Ltd., Shanghai, China.
- Bionova (Shanghai) Medical Technology Co., Ltd, Shanghai, China.
- Department of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
ORCID-Profile: Chang Chen
Förderung
- Shanghai Pulmonary Hospital Innovation Team
- Shanghai Science and Technology Committee
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Ren, Y., Zhang, Z., She, Y., He, Y., Li, D., Shi, Y., He, C., Yang, Y., Zhang, W., & Chen, C. (2024). A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer. Small Methods. https://doi.org/10.1002/smtd.202300747
Vancouver
Ren Y, Zhang Z, She Y, He Y, Li D, Shi Y, et al. A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer. Small Methods. 2024. doi:10.1002/smtd.202300747
BibTeX
@article{Ren2024,
author = {Ren, Yijiu and Zhang, Zhou and She, Yunlang and He, Yayi and Li, Dongdong and Shi, Yixiang and He, Chuan and Yang, Yang and Zhang, Wei and Chen, Chang},
title = {A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer},
journal = {Small Methods},
year = {2024},
doi = {10.1002/smtd.202300747}
}
EUVIMED